Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Liver Histology01:27

Liver Histology

The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

In Vitro TLR4 Stimulating Bioactivities of Amylase/Trypsin-Inhibitors from Wheat (<i>Triticum aestivum</i> L.) Bred from 1891 to 2010.

Foods (Basel, Switzerland)·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.

United European gastroenterology journal·2026
Same author

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.

BMC medicine·2026
Same author

Sex-related differences in cardiovascular inflammation and metabolomics in a humanized transgenic mouse model of celiac disease.

Scientific reports·2026
Same author

ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis.

Hepatology (Baltimore, Md.)·2026

相关实验视频

肝硬化是肝硬化的一种疾病.

Detlef Schuppan1, Nezam H Afdhal

  • 1Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dschuppa@bidmc.harvard.edu

Lancet (London, England)
|March 11, 2008
PubMed
概括
此摘要是机器生成的。

肝硬化是一种严重的肝脏疾病,由于了解其进展和并发症的进步,正在得到更好的管理. 新的治疗方法旨在阻止或逆转肝病,改善患者的结果超出移植.

相关实验视频

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 内部医学 内部医学
  • 病理生理学 病理生理学

背景情况:

  • 肝硬化是由慢性损伤造成的肝脏痕的特征,导致门门高血压和末期肝脏疾病.
  • 最近的科学理解改善了肝硬化患者的管理,生活质量和生存率.
  • 虽然肝移植对一些人来说是治愈的,但正在出现新的药理方法来阻止或逆转肝病的进展.

研究的目的:

  • 提供关于肝硬化诊断,并发症和管理的全面概述.
  • 突出最近临床和科学进步,了解和治疗肝硬化.
  • 讨论开发用于肝脏疾病的新型药理疗法.

主要方法:

  • 关于肝硬化病理生理学和自然史的当前文献的综述.
  • 对新兴肝硬化治疗的最近临床试验数据的分析.
  • 综合有关诊断和管理策略的专家知识.

主要成果:

  • 通过更好地管理肝硬化并发症,改善了患者的治疗结果和预期寿命.
  • 开发药理学药剂,显示其有可能阻止或逆转肝纤维化.
  • 确定肝移植作为对特定患者的关键治疗选择.

结论:

  • 了解肝硬化的进展正在改善患者的护理和预后.
  • 药物治疗正在地平线上,有可能扭转肝损伤.
  • 多方面的方法,包括移植和新疗法,对于管理晚期肝病至关重要.